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Summary	Renal	 Fanconi	 Syndrome	 (RFS)	 refers	 to	 the	 generalised	 dysfunction	 of	 the	proximal	tubule	(PT)	[1].	In	its	isolated	form,	RFS	only	affects	the	PT,	but	not	the	other	 nephron	 segments.	 The	 study	 of	 isolated	 RFS	 can	 thus	 provide	 specific	insights	 into	 the	 function	 of	 the	 PT.	 In	 a	 recent	 paper,	 Klootwijk	 et	 al.,	investigated	 one	 such	 form	 of	 isolated	 RFS	 and	 revealed	 the	 underlying	molecular	 basis	 [2].	 The	 affected	 family	 had	 been	 described	 previously,	demonstrating	 the	 typical	 features	 of	 RFS,	 such	 as	 low-molecular	 weight	proteinuria,	 aminoaciduria,	 glycosuria	 and	 phosphaturia	 with	 consequent	rickets;	 yet,	 importantly,	 patients	 had	 no	 evidence	 of	 impaired	 glomerular	filtration	 [3].	 Inheritance	 was	 consistent	 with	 an	 autosomal	 dominant	 mode.	Klootwijk	 et	 al.	 discovered	 a	 surprising	 explanation:	 a	 heterozygous	missense	mutation	 causing	 partial	 mistargeting	 of	 the	 peroxisomal	 enzyme	 EHHADH	 to	the	mitochondria.	Notably,	disease	causing	was	not	the	absence	of	the	enzyme	in	the	peroxisome,	but	its	interference	with	mitochondrial	function.	The	discovery	of	 this	 novel	 disease	 mechanism	 not	 only	 confirmed	 the	 importance	 of	mitochondrial	 function	 for	 PT	 transport,	 but	 also	 demonstrated	 the	 critical	dependence	of	PT	on	fatty	acid	metabolism	for	energy	generation.			
The	review:	
Proximal	tubule:	function	and	physiology	In	an	average	adult,	the	kidneys	(glomeruli)	generate	approximately	150	litres	of	filtrate	 per	 day,	 of	 which	 about	 99%	 is	 reabsorbed	 by	 the	 tubules,	 yielding	 a	urine	 volume	 of	 1-2	 litres	 (Figure	 1)	 [4].	 The	 vast	majority	 of	 the	 glomerular	filtrate	 is	 reabsorbed	 by	 the	 PT,	 the	 “workhorse”	 of	 tubular	 segments.	 Insight	
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into	 the	 contributions	 of	 the	 individual	 nephron	 segments	 has	 been	 mainly	provided	by	micropuncture	experiments,	where	micropipettes	are	inserted	into	different	 segments	 of	 the	 nephron	 to	 measure	 flow	 and	 obtain	 samples	 for	analysis.	This	technique	has	an	important	limitation,	however,	in	that	only	those	segments	that	are	close	to	the	surface	of	the	kidney	are	accessible	for	puncture.	Thus,	the	last	accessible	site	in	PT	is	the	end	of	the	proximal	convolute	and	the	next	accessible	 site	downstream	 is	 the	beginning	of	 the	distal	 convolute	 [5].	 In	between	 these	 two	 sites	 is	 the	 straight	 descending	 PT	 (the	 pars	 recta	 or	 S3	segment)	and	the	loop	of	Henle	and	it	is	impossible	to	accurately	determine	the	individual	 contributions	 of	 these	 segments.	Whilst	 the	 function	 of	 all	 nephron	segments	 including	 those	 not	 accessible	 by	 the	 micropuncture	 technique	 has	been	 studied	 using	 the	 technique	 of	 isolated	 tubule	 perfusion,	 quantitative	information	 with	 respect	 to	 relative	 transport	 activity	 in	 vivo	 is	 difficult	 to	extrapolate	[6].	In	any	case,	the	PT	not	only	reabsorbs	the	vast	majority	of	filtrate	in	terms	of	salt	and	water,	 but	 also	 is	 the	 sole	 site	 of	 reabsorption	 for	many	 valuable	 solutes,	such	 as	 amino-	 and	 organic	 acids,	 filtered	 proteins,	 glucose	 and	 phosphate.	 In	quantitative	 terms,	without	 a	 functional	 PT,	we	would	 lose	 approximately	 120	litres	 of	 water	 per	 day,	 plus	 solutes,	 including	 about	 18	 mol	 of	 sodium	 (the	equivalent	 of	 roughly	 1	 kg	 of	 cooking	 salt)	 and	more	 than	 100	 g	 of	 sugar.	 In	addition,	 all	 the	 filtered	 amino	 acids	would	be	 lost,	 deficiency	 of	which	 can	be	associated	with	specific	diseases	[7],	as	well	as	all	filtered	phosphate,	resulting	in	hypophosphataemic	 rickets.	 In	 short:	 the	 PT	 is	 important	 for	 our	 survival!	 In	addition,	 it	 becomes	 evident	 from	 those	 numbers	 that	 RFS	 refers	 to	 an	impairment	of	PT	function,	rather	than	a	complete	absence	of	function.		
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The	 enormous	 reabsorptive	 capacity	 is	 provided	 by	 a	 whole	 orchestra	 of	specialised	apical,	basolateral	and	paracellular	permeabilities	and	driven	by	the	electrochemical	gradient	generated	by	the	basolateral	Na+-K+-ATPase	(see	Figure	2).	 Not	 surprisingly,	 the	 PT	 has	 a	 high	 energy	 demand	 to	 keep	 the	 transport	going,	which	may	explain,	why	it	is	also	the	nephron	segment	most	susceptible	to	ischaemic	damage	[8].	Understanding	PT	function	thus	will	not	only	elucidate	the	pathophysiology	 of	 the	 rare	 RFS,	 but	may	 also	 provide	 insights	 into	 the	more	common	problem	of	acute	kidney	injury	[9].		
RFS:	the	history	Rickets	and	albuminuria	secondary	to	kidney	disease	was	first	described	in	1881	but	 attributed	 to	 be	 a	 “disorder	 of	 adolescence”	 [10].	 It	 was	 the	 Swiss	paediatrician	Guido	Fanconi,	who	first	described	the	concept	that	defective	renal	proximal	 tubule	 reabsorption	 of	 solutes	 might	 contribute	 to	 “non-nephrotic	glycosuric	 dwarfing	 with	 hypophosphataemic	 rickets	 in	 early	 childhood”	 [11].	Fanconi’s	first	case	presented	at	the	age	of	3	months	with	rickets	and	recurrent	fevers.	 She	 had	 glycosuria	 and	 albuminuria	 and	 progressed	 to	 terminal	 renal	failure	by	5	years	of	age	and	subsequently	died.	At	autopsy	the	renal	tubule	cells	appeared	 filled	with	 crystals,	which	were	 thought	 to	be	 cystine.	 In	 subsequent	reports,	Debré,	de	Toni	and	Fanconi	all	described	series	of	children	with	rickets,	glycosuria	and	albuminuria	[12-14].	In	acknowledgment	of	this	pioneering	work,	RFS	 is	 also	 referred	 to	 as	 Fanconi-Debré-de	 Toni	 syndrome,	 but	 in	 clinical	practice	 most	 people	 use	 the	 shorter	 name.	 The	 presentation,	 course	 and	outcome	of	 the	 children	described	 in	 these	 early	descriptions	 varied	markedly	and	 this	 concurs	with	 our	 clinical	 experience	now.	 It	 reflects	 that	RFS	 is	 not	 a	
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uniform	 entity,	 but	 a	 diagnosis	 of	 proximal	 tubular	 dysfunction,	 which	 can	 be	due	 to	 a	 variety	 of	 different	 causes.	 RFS	 can	 be	 isolated,	 such	 as	 in	 the	 family	investigated	by	Klootwijk	et	al.,	or	in	the	context	of	multiorgan	disorders,	such	as	nephropathic	 cystinosis	 or	 mitochondrial	 cytopathies;	 it	 can	 be	 congenital	 or	acquired,	 transient	 or	 permanent,	 associated	 with	 progression	 to	 end-stage	kidney	disease	(ESKD)	or	with	stable	glomerular	filtration	[15-17].	Moreover,	it	can	 differ	 in	 the	 extent	 and	 severity	 of	 tubular	 dysfunction.	 Severe	 and	generalised	 PT	 dysfunction	 is	 seen	 in	 nephropathic	 cystinosis,	 whilst	 some	patients	with	e.g.	Dent	disease	or	Lowe	syndrome	have	wasting	of	low-molecular	weight	 proteins	 and	 calcium,	 yet	 without	 clinically	 significant	 disturbance	 of	phosphate	and	bicarbonate	transport	[18].	Indeed,	there	is	some	debate	at	what	point	 proximal	 tubular	 dysfunction	 can	 be	 called	 RFS	 [1].	 There	 seems	 to	 be	agreement	 that	 several	 individual	 PT	 functions	 have	 to	 be	 compromised	 and	isolated	 renal	 tubular	 aminoacidurias	 (e.g.,	 cystinuria	 or	 Hartnup	 disorder)	would	 not	 be	 labelled	 as	 renal	 Fanconi	 syndrome.	 Dissecting	 the	 various	pathways	 involved	 in	 these	 individual	 diseases	 of	 course	 contributes	 to	 our	understanding	of	PT	function.		
RFS:	the	inheritance	There	are	several	genetic	forms	of	RFS,	the	majority	of	which	are	associated	with	multisystem	 disorders	 (Table	 1).	 In	 general,	 the	 disease	 mechanism	 for	 these	disorders	can	be	categorised	as	either	a)	accumulation	of	a	toxic	metabolite	(e.g.	cystinosis,	 tyrosinaemia,	 galactosaemia,	 Fanconi-Bickel,	 congenital	 fructose	intolerance	 and	 Wilson’s	 disease),	 b)	 disruption	 of	 energy	 provision	 (e.g.	
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mitochondrial	 cytopathies)	 or	 c)	 disruption	 of	 endocytosis	 and	 intracellular	transport	(e.g.	Lowe	syndrome,	Dent	disease	and	ARC	syndrome).	Recently,	 RFS	 was	 described	 in	 some	 patients	 with	 MODY1	 (“maturity-onset	diabetes	of	the	young”	type	1)	[19].	Interestingly,	this	renal	phenotype	was	seen	only	in	patients	with	a	specific	heterozygous	mutation,	R76W	in	HNF4A,	whereas	those	patients	with	other	mutations	in	HNF4A	suffered	from	pancreatic	beta	cell	dysfunction	only.	 Since	HNF4A	 is	 a	 transcription	 factor,	 this	 finding	 suggests	 a	specific	 effect	 of	 the	 R76W	 mutation	 on	 transcription	 of	 certain	 genes	 in	 the	kidney,	but	which	ones	exactly	are	affected	is	unknown.	Of	special	interest	are,	of	course,	the	forms	of	isolated	RFS,	as	these	may	provide	the	 most	 specific	 insight	 into	 PT	 function.	 Three	 genetic	 forms	 have	 been	described	(Table	1):	Fanconi	Renotubular	Syndrome	(FRTS)	types	1-3.	The	first	one	was	published	already	in	2001,	including	linkage	to	a	locus	on	chromosome	15,	yet	identification	of	the	underlying	gene	is	yet	awaited	[20].	Of	note,	FRTS1	is	also	 associated	 with	 progressive	 chronic	 kidney	 disease	 (CKD).	 Thus,	identification	of	the	underlying	problem	may	also	elucidate	a	mechanism	of	CKD	progression.	Other	families	with	a	similar	phenotype	of	RFS	and	progressive	CKD	inherited	in	an	autosomal	dominant	fashion	had	been	described	previously	[21-23],	suggesting	that	this	may	be	a	slightly	more	common	form	of	these	otherwise	very	rare	diseases.	FRTS2	has	so	far	been	described	only	in	2	siblings.	An	initial	clinical	description	was	 provided	 in	 1988	 [24],	 revealing	 a	 phenotype	 dominated	 by	 phosphate	wasting	and	rickets	despite	elevated	levels	of	1,25	OH	vitamin	D	with	associated	disturbances	 of	 some,	 but	 not	 all	 PT	 transport	 pathways,	 as	 e.g.	 renal	 tubular	acidosis	was	not	present	,	raising	again	the	question	of	what	constitutes	RFS	[1].	
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In	2010,	an	underlying	mutation	was	reported	in	form	of	a	homozygous	in-frame	21	bp	duplication	in	SLC34A1,	encoding	the	phosphate	transporter	NaPi-IIa	[25].	In	 vitro	 studies	 demonstrated	 significant	 loss-of-function	 of	 the	 mutant	transporter.	The	finding	of	SLC34A1	mutations	in	RFS	has	been	surprising,	given	that	mutations	in	SLC34A3,	encoding	another	renal	phosphate	transporter	NaPi-IIc,	 cause	 hereditary	 hypophosphataemic	 rickets	 with	 hypercalciuria	 [26].	 No	further	patients	with	RFS	and	recessive	mutations	in	SLC34A1	have	so	far	been	reported.	 The	 genetic	 finding,	 however,	 is	 consistent	 with	 the	 clinical	observation	 of	 phosphate	 wasting	 and	 rickets	 being	 the	 key	 clinical	abnormalities	in	these	two	siblings	and	that	the	phenotype	could	be	ameliorated	by	phosphate	supplementation.	The	underlying	mechanism	may	be	intracellular	phosphate	depletion	with	consequent	insufficient	ATP	generation.	Abnormalities	in	 an	 unrelated	 proximal	 transport	 pathway	 has	 been	 observed	 in	 mice	 with	hypophosphataemic	rickets	[27]	and	glycosuria	is	indeed	a	common	observation	in	 patients	 with	 hypophosphataemic	 rickets	 in	 our	 own	 clinical	 practice.	However,	 other	 indicators	 of	 PT	 dysfunction,	 such	 as	 low-molecular	 weight	proteinuria	are	normal	in	these	patients	(unpublished	own	observations).	FRTS3	 is	 the	 form	of	 isolated	RFS	 that	was	 investigated	by	our	 laboratory	and	reported	by	Klootwijk	et	al.	[2].	We	studied	the	five	generation	family	described	by	 Tolaymat	 et	 al.	 [3].	 Reassessment	 of	 the	 clinical	 phenotype	 confirmed	 the	original	 observations	 made	 by	 Tolaymat	 et	 al..	 Moreover,	 it	 demonstrated	normal	 age-appropriate	 GFR	 in	 all	 affected	 family	 members,	 including	 the	 by	then	74-year	old	matriarch.	This	alone	provided	valuable	 insights:	 the	 life-long	loss	 of	 water	 and	 solutes,	 including	 about	 1g/d	 of	 filtered	 proteins	 does	 not	appear	to	be	a	critical	risk	factor	for	the	development	of	CKD.	
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With	 respect	 to	 revealing	 the	 underlying	 genetic	 cause	 we	 first	 performed	linkage	analysis,	which	identified	a	single	locus	on	chromosome	3.	Sequencing	of	all	known	genes	within	this	locus	revealed	a	heterozygous	missense	mutation	in	a	 gene	 called	 EHHADH	 that	 segregated	 with	 the	 disease.	 EHHADH	 encodes	 a	bifunctional	enzyme	 involved	 in	peroxisomal	 fatty	acid	metabolism	(also	called	L-PBE	for	L-peroxisomal	bifunctional	enzyme).	The	identification	of	EHHADH	as	the	underlying	gene	was	initially	surprising:	the	patients	did	not	have	a	clinical	phenotype	 consistent	 with	 a	 peroxisomal	 disorder,	 which	 typically	 comprises	severe	CNS	involvement	[28].	Moreover,	the	function	of	Ehhadh	in	mice	appears	to	 be	 at	 least	 partially	 redundant,	 as	 knock-out	mice	 do	 not	 have	 an	 apparent	abnormal	phenotype,	except	 for	some	changes	 in	 lipid	metabolites	after	 fasting	[29].	They	only	develop	a	relevant	clinical	phenotype,	when	the	related	enzyme	D-PBE	is	also	deleted	[30,	31].	So	how	does	a	heterozygote	missense	mutation	in	a	gene	cause	disease,	when	we	know	that	complete	loss-of-function	can	easily	be	tolerated	(at	least	in	mice)?	The	solution	to	this	conundrum	came	closer	with	the	realisation	that	the	identified	mutation	(c.7G>A,	p.E3K)	introduced	a	de	novo	N-terminal	 mitochondrial	 targeting	 motif	 and	 indeed,	 subsequent	 cell-biological	studies	confirmed	a	mitochondrial	localisation	of	the	mutated	enzyme.		Could	the	mutant	 enzyme	 perhaps	 impair	 the	 function	 of	 the	 erroneously	 targeted	organelle,	 the	 mitochondria?	 To	 address	 this	 question,	 we	 performed	respirometry	 in	 proximal	 tubular	 cells	 expressing	 either	 wild	 type	 or	 mutant	EHHADH,	 which	 indeed	 demonstrated	 a	 significantly	 decreased	 capacity	 for	oxidative	phosphorylation	in	the	mutant	cells	compared	to	wild	type,	compatible	with	 a	 defect	 in	 ATP	 production.	 Thus,	 we	 concluded	 that	 mistargeting	 of	EHHADH	 led	 to	 a	 dominant	 negative	 effect	 on	 mitochondrial	 function,	
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presumably	 by	 interference	with	 the	mitochondrial	 trifunctional	 enzyme.	 This	enzyme	 is	 a	multimeric	 protein	 involved	 in	mitochondrial	 fatty	 acid	 oxidation	and	has	a	high	degree	of	homology	 to	EHHADH,	so	 that	erroneous	assembly	of	mutant	 mislocalised	 EHHADH	 into	 this	 enzyme	 may	 occur.	 Subsequent	 co-immunoprecipitation	 experiments	 confirmed	 an	 association	 of	mutant	 but	 not	wild	 type	EHHADH	with	 two	subunits	of	 the	 trifunctional	enzyme,	HADHA	and	HADHB.	This	 dominant	 negative	 effect	 of	 mistargeting	 constitutes	 a	 previously	unrecognised	 disease	 mechanism.	 Mistargeting	 of	 a	 peroxisomal	 enzyme	 to	mitochondria	had	been	described	as	a	disease	mechanism	with	a	specific	variant	in	 AGXT,	 causing	 primary	 hyperoxaluria	 [32].	 However,	 in	 this	 recessive	disorder,	 it	 is	 the	absence	of	peroxisomal	AGXT	activity	 that	 is	disease	causing	rather	than	interference	with	mitochondrial	function,	as	seen	in	FRTS3.	A	 key	 question,	 however,	 remained:	 why	 did	 the	 affected	 patients	 develop	 an	isolated	 renal	 phenotype,	when	 the	 enzyme	 is	 also	 expressed	 in	 other	 tissues?	Should	not	a	generalised	mitochondrial	phenotype	be	present?		
Energy	politics	of	the	proximal	tubule	The	explanation	for	this	conundrum	may	have	several	components.	One	relates	to	 the	 magnitude	 of	 the	 observed	 impairment	 in	 mitochondrial	 function:	 the	capacity	 for	 oxidative	 phosphorylation	 was	 reduced	 by	 approximately	 25%;	while	this	was	significant,	it	may	be	disease-causing	(i.e.	relevant)	only	in	those	tissues	with	a	high	metabolic	demand,	such	as	the	PT.	Yet	a	probably	much	more	important	 component	 is	 a	unique	 feature	of	PT	 fuel	 consumption:	 the	PT	does	not	 utilise	 glucose,	 but	 is	 dependent	 on	 fatty	 acid	metabolism	 [33]!	 This	 may	
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reflect	an	evolutionary	development	to	maximise	glucose	provision	to	the	brain,	in	 that	all	 filtered	glucose	 is	 returned	 into	 the	bloodstream.	However,	 it	makes	the	PT	uniquely	susceptible	to	disturbances	in	fatty	acid	metabolism,	consistent	with	the	phenotype	of	FRTS3.		
Future	research	questions	The	 discovery	 of	 new	 disease	 genes	 and	 mechanisms	 often	 generate	 more	questions	than	answers.	Whilst	the	clinical	and	genetic	data	are	clear,	the	precise	nature	of	the	mechanism	requires	further	investigations:	Is	 there	 biochemical	 evidence	 for	 disturbed	 fatty	 acid	 metabolism?	 Obtaining	these	data	from	the	patients	would	likely	be	difficult,	as	plasma	levels	reflect	the	overall	 metabolism,	 rather	 than	 the	 specific	 metabolites	 generated	 in	 PT.	However,	the	question	could	be	addressed	in	the	cell	culture	system	developed	in	 our	 lab.	 Alternatively,	 cell	 lines	 could	 be	 established	 from	 proximal	 tubular	cells	shed	in	the	urine,	as	described	in	other	disorders	[34].	PT	cells	as	model	to	study	these	questions	need	to	be	differentiated	as	only	then	glucose	metabolism	reflects	the	situation	of	the	PT	in	vivo.	This	is	not	the	case	for	many	PT	cell	lines,	especially	not	if	they	are	not	differentiated	on	permeable	supports.	Given	 the	 insight	 provided	 by	 the	 investigation	 of	 FRTS3,	 a	 key	 question	 is,	 of	course,	 the	 nature	 of	 the	 disease	 mechanism	 in	 another	 form	 of	 RFS,	 FRTS1.	What	is	the	underlying	gene	and	how	does	it	cause	RFS	and	CKD?	Last,	but	not	least:	what	lessons	from	the	study	of	rare	disease	can	be	translated	to	benefit	 the	 treatment	of	common	disease?	RFTS3	clearly	has	highlighted	the	importance	 of	 fatty	 acid	 metabolism	 for	 PT	 function.	 Could	 this	 be	 used	therapeutically,	e.g.	in	the	prevention	or	treatment	of	acute	kidney	injury	(AKI)?	
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Table	1:	Genetic	forms	of	RFS	
	
Systemic	disorders	
Gene	 OMIM	 Disorder	 Associated	Features	
GALT	 230400	 Galactosemia	 Liver	 dysfunction,	 jaundice,	encephalopathy,	sepsis	Multiple	nuclear	 and	mitochondrial	DNA	variants	
multiple		 Mitochondrial	cytopathies	 Usually	 multisystem	dysfunction	 (brain,	 muscle,	liver,	heart)	
FAH	 276700	 Tyrosinemia	 Poor	 growth,	 hepatic	enlargement	 and	 dysfunction,	liver	cancer	
ALDOB	 229600	 Congenital	Fructose	Intolerance	 Rapid	 onset	 after	 fructose	ingestion,	 vomiting,	hypoglycemia,	hepatomegaly	
CTNS	 219800	 Cystinosis	 Poor	growth,	vomiting,	rickets	±	corneal	 cystine	 crystals,	 kidney	failure	
GLUT2	 227810	 Fanconi	 Bickel	syndrome	 Failure	to	thrive,	hepatomegaly,	hypoglycemia,	rickets	
OCRL	 309000	 Lowe’s	syndrome	 Males	 (X-linked),	 cataracts,	hypotonia,	developmental	delay	
CLCN5,	OCRL	 300009,	300555	 Dent	 disease	 I,	II	 Males	 (X-linked),	hypercalciuria,	nephrocalcinosis	
ATP7B	 277900	 Wilson’s	disease	 Hepatic	 &	 neurological	 disease,	Kayser-Fleischer	rings	
VPS33B,	VIPAR	 208085,	613404	 ARC	syndrome	 Arthrogryposis,	 platelet	abnormalities,	cholestasis	
HNF4A	 125850	 MODY1	 neonatal	 hyperinsulinism,	Maturity-onset	 of	 diabetes	 in	the	 young,	 mutation	 R76W	shows	RFS	
Isolated	RFS	 	 	 	?	 134600	 FRTS1	 glomerular	kidney	failure	
SLC34A1	 613388	 FRTS2	 phosphaturia	dominating	
EHHADH	 615605	 FRTS3	 no	kidney	failure	
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Table	2:	Key	points	
• FRTS3	is	caused	by	a	mutation	in	EHHADH	
• Discovery	of	a	novel	disease	mechanism:	a	dominant	negative	effect	from	intracellular	mistargeting	of	the	mutated	enzyme	
• Life	 long	 dysfunction	 of	 PT	 including	 the	 loss	 of	 about	 1g/d	 of	 filtered	proteins	alone	does	not	cause	chronic	kidney	disease	
• The	 proximal	 tubule	 is	 dependent	 on	 fatty	 acid	 metabolism	 for	 energy	generation	
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Figure	 1:	 Genetic	 renal	 tubular	 diseases	 caused	 by	 failure	 of	 sodium	
reabsorption	in	individual	nephron	segments		
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Figure	 2:	 Simplified	 schematic	 of	 renal	 proximal	 tubular	 cell	 with	 key	
transepithelial	transport	systems	(note,	Cl-	and	HCO3--transport	systems	have	been	omitted).		
	
	
